These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34201065)

  • 1. Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination.
    Puro V; Castilletti C; Agrati C; Goletti D; Leone S; Agresta A; Cimini E; Tartaglia E; Casetti R; Colavita F; Meschi S; Matusali G; Lapa D; Najafi Fard S; Aiello A; Farrone C; Gallì P; Capobianchi MR; Ippolito G; On Behalf Of The Inmi Covid-Vaccine Study Group
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34201065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
    Isgrò MA; Trillò G; Russo L; Tornesello AL; Buonaguro L; Tornesello ML; Miscio L; Normanno N; Bianchi AAM; Buonaguro FM; Cavalcanti E;
    Infect Agent Cancer; 2022 Jul; 17(1):40. PubMed ID: 35902961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
    Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
    Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination strategy and anti - SARS-CoV-2 S titers in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
    Cavalcanti E; Isgrò MA; Rea D; Di Capua L; Trillò G; Russo L; Botti G; Miscio L; Buonaguro FM; Bianchi AAM
    Infect Agent Cancer; 2021 May; 16(1):32. PubMed ID: 33980271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis.
    Goupil R; Benlarbi M; Beaubien-Souligny W; Nadeau-Fredette AC; Chatterjee D; Goyette G; Gunaratnam L; Lamarche C; Tom A; Finzi A; Suri RS;
    CMAJ; 2021 May; 193(22):E793-E800. PubMed ID: 33980499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2.
    Salvaggio M; Fusina F; Albani F; Salvaggio M; Beschi R; Ferrari E; Costa A; Agnoletti L; Facchi E; Natalini G
    J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study.
    Vollenberg R; Tepasse PR; Lorentzen E; Nowacki TM
    J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine.
    Agrati C; Castilletti C; Goletti D; Meschi S; Sacchi A; Matusali G; Bordoni V; Petrone L; Lapa D; Notari S; Vanini V; Colavita F; Aiello A; Agresta A; Farroni C; Grassi G; Leone S; Vaia F; Capobianchi MR; Ippolito G; Puro V; On Behalf Of The Inmi Covid-Vaccine Study Group
    Microorganisms; 2021 Jun; 9(6):. PubMed ID: 34208751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
    Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
    ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
    Lasagna A; Agustoni F; Percivalle E; Borgetto S; Paulet A; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Lilleri D; Secondino S; Falzoni M; Schiavo R; Klersy C; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2021 Oct; 6(5):100272. PubMed ID: 34543863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers.
    Salvagno GL; Henry BM; di Piazza G; Pighi L; de Nitto S; Bragantini D; Gianfilippi GL; Lippi G
    J Med Biochem; 2021 Sep; 40(4):327-334. PubMed ID: 34616222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine.
    Coppeta L; Ferrari C; Somma G; Mazza A; D'Ancona U; Marcuccilli F; Grelli S; Aurilio MT; Pietroiusti A; Magrini A; Rizza S
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents-The Data from the Study among Healthcare Workers in an Infectious Diseases Center.
    Skrzat-Klapaczyńska A; Kowalska JD; Paciorek M; Puła J; Bieńkowski C; Krogulec D; Stengiel J; Pawełczyk A; Perlejewski K; Osuch S; Radkowski M; Horban A
    Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis.
    Espi M; Charmetant X; Barba T; Koppe L; Pelletier C; Kalbacher E; Chalencon E; Mathias V; Ovize A; Cart-Tanneur E; Bouz C; Pellegrina L; Morelon E; Fouque D; Juillard L; Thaunat O
    Kidney Int; 2021 Oct; 100(4):928-936. PubMed ID: 34284044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Dynamics of SARS-CoV-2 IgG Antibody Responses after the Two-Dose Regimen of BNT162b2 Vaccination and the Effect of a Third Dose on Healthcare Workers in Japan.
    Sakamoto A; Yoshimura M; Itoh R; Ozuru R; Ishii K; Sechi Y; Nabeshima S; Hiromatsu K
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination.
    Salvagno GL; Henry BM; di Piazza G; Pighi L; De Nitto S; Bragantini D; Gianfilippi GL; Lippi G
    Diagnostics (Basel); 2021 May; 11(5):. PubMed ID: 34064509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Influenza Vaccination on the Response to BNT162b2 Messenger RNA COVID-19 Vaccine in Healthcare Workers.
    Greco M; Cucci F; Portulano P; Lazzari RA; Caldararo C; Sicuro F; Catanese C; Lobreglio G
    J Clin Med Res; 2021 Dec; 13(12):549-555. PubMed ID: 35059073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine.
    Lo Sasso B; Giglio RV; Vidali M; Scazzone C; Bivona G; Gambino CM; Ciaccio AM; Agnello L; Ciaccio M
    Diagnostics (Basel); 2021 Jun; 11(7):. PubMed ID: 34206567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart.
    Modenese A; Paduano S; Bargellini A; Bellucci R; Marchetti S; Bruno F; Grazioli P; Vivoli R; Gobba F
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34203652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
    Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.